Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S-adenosylmethionine (SAMe) is a naturally occurring compound in the human body formed from methionine and adenosine triphosphate. It acts as a major methyl group donor in numerous biochemical reactions including the synthesis of DNA and RNA nucleic acids, phospholipids, proteins, neurotransmitters (such as epinephrine), melatonin, and creatine. In clinical use—primarily outside the United States—SAMe is prescribed for depression, osteoarthritis, fibromyalgia, and various liver disorders. In the U.S., it is available as an over-the-counter dietary supplement rather than a regulated pharmaceutical drug. Its mechanism of action involves transmethylation processes that support cellular growth and repair and influence hormone/neurotransmitter function[1][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on S-adenosylmethionine.